Scope
The EULAR 2023 update, published in 2024, sets a treat-to-target pharmacological pathway for psoriatic arthritis. Peripheral arthritis, enthesitis and axial disease follow different escalation routes, while psoriasis, uveitis, inflammatory bowel disease and individual safety risks help determine the drug class. The guidance emphasizes shared decisions and regular reassessment.
Written by House with AI assistance · AI-assisted source check 29 October 2026.
This is House’s summary of the cited guidance. The source check is not an independent clinician review. Open the publication for complete recommendations, exceptions, evidence grades and later amendments.
Treat the full phenotype and agree a target
- Aim for remission or low disease activity using regular assessment and treatment adjustment. Review the active domains—joints, skin, enthesitis, dactylitis and axial disease—rather than assuming one measure captures the entire illness. [1]
- Base treatment on a shared decision considering efficacy, safety, preferences and costs. Rheumatologists should lead musculoskeletal care and collaborate with dermatology for clinically relevant skin involvement; also consider eye, bowel, metabolic, cardiovascular and mental-health problems. [1]
- NSAIDs may relieve musculoskeletal symptoms and local glucocorticoid injections may be adjuncts. These are symptomatic measures, not substitutes for disease-modifying therapy in most patients; account for NSAID toxicity and comorbidity. [1]
- NSAID-only treatment is mainly for very mild peripheral or predominant entheseal/axial disease and usually brief, approximately 4 weeks. Continuing NSAIDs for axial disease may be reasonable when symptoms improve substantially and the benefit–risk balance remains favorable. [1]
Escalate peripheral arthritis treatment appropriately
- Start a conventional synthetic DMARD promptly for polyarthritis or mono/oligoarthritis with poor prognostic features such as structural damage, raised inflammatory markers, dactylitis or nail involvement. Prefer methotrexate when skin disease is clinically relevant. [1]
- Oligoarticular disease without poor prognostic factors should also receive a conventional DMARD, but initiation is less urgent and a period of symptomatic treatment may precede it. Treat isolated dactylitis similarly to oligoarthritis, including local injections and conventional DMARD options. [1]
- Reassess conventional-DMARD efficacy at about 12 weeks. The treat-to-target framework expects at least 50% activity improvement by 3 months and achievement of the target by 6 months; escalate when these goals are not met rather than persisting with ineffective monotherapy. [1]
- Use an adequate methotrexate dose with folate supplementation and regular benefit–risk assessment, especially for hepatotoxicity in patients with metabolic risk. Leflunomide or sulfasalazine are alternatives for peripheral arthritis; the methotrexate–leflunomide combination is not recommended here. [1]
- For peripheral arthritis inadequately controlled by at least one conventional DMARD, commence a biologic DMARD. With limited peripheral disease and no poor prognostic factors, a second conventional-DMARD course may be reasonable if patient and prescriber agree. [1]
- There is no preferred biologic class for joint efficacy alone, but extra-musculoskeletal disease guides selection. All biologics increase infection risk; candidiasis is more frequent with IL-17 pathway inhibition, and class-specific safety and comorbidity must inform prescribing. [1]
- For peripheral arthritis after inadequate response to at least one biologic, or when biologics are inappropriate, a JAK inhibitor may be considered after safety review. The update generally places JAK inhibitors after biologics, rather than routinely at the same escalation step. [1]
- Apply particular JAK-inhibitor caution at age ≥65, with current or past long-term smoking, atherosclerotic disease or other cardiovascular risks, malignancy risks, or venous-thromboembolism risks. These precautions apply when JAK inhibition is considered in any PsA pathway. [1]
- Consider a PDE4 inhibitor for mild disease only after inadequate response to at least one conventional DMARD when neither a biologic nor a JAK inhibitor is appropriate. Here, mild means oligoarticular or entheseal disease without poor prognostic factors and with limited skin involvement. [1]
Select treatment for enthesitis, axial and extra-articular disease
- For unequivocal enthesitis unresponsive to NSAIDs or local injections, consider a biologic. Establish true entheseal inflammation, using imaging if needed, to avoid escalating treatment for widespread pain or mechanical stress alone. [1]
- For clinically relevant axial disease after inadequate NSAID response, consider an IL-17A, TNF, IL-17A/F or JAK inhibitor, with JAK safety precautions. These are alternatives, not a combination; conventional DMARDs are not relevant to the axial pathway. [1]
- With clinically relevant psoriasis, favor IL-17A, IL-17A/F, IL-23 or IL-12/23 targeting. Skin disease can be relevant because of extensive involvement or major patient impact, including facial or genital disease, even when the total area is limited. [1]
- For associated uveitis, prefer an anti-TNF monoclonal antibody. For coexisting inflammatory bowel disease, choose an appropriate licensed anti-TNF monoclonal, IL-23, IL-12/23 or JAK option with specialist input and safety review; IL-17 inhibitors are not recommended in active bowel disease. [1]
Switch for failure and taper cautiously in remission
- After inadequate response or intolerance to a biologic or JAK inhibitor, consider another biologic or JAK inhibitor, including a switch within the same class. The recommendation does not prescribe a fixed total number of switches; retain individual safety assessment. [1]
- Do not combine biologic DMARDs routinely: the update describes such combinations as investigational and not currently recommendable. Apremilast plus a TNF inhibitor likewise lacks supporting data and is not recommended. [1]
- In sustained remission, DMARD tapering may be considered through shared decision-making. The intended approach is dose reduction, not stopping treatment, because discontinuation commonly causes flares; tapering is optional and long-term evidence remains limited. [1]
Limitations and use
- This guideline addresses non-topical pharmacological treatment; it is not a complete non-drug, dermatological or prescribing protocol. Infection screening, contraindications, laboratory monitoring, pregnancy planning and individual medicine eligibility require current product and specialist guidance. Drug indications cited by this earlier update should not be treated as a current licence list. Its JAK safety precautions partly extrapolate evidence from rheumatoid arthritis.
This summary is selective and does not reproduce every recommendation. Apply the source’s population, setting and eligibility criteria, together with clinical judgement and local policy.
Summary sources
- Psoriatic arthritis: pharmacological management — 2023 update
Selected recommendation material consulted
Publication details
- Issuing organisation
- EULAR
- First published
- 18 March 2024
- Resource type
- Clinical guideline · House clinical summary
The source check confirms publication details and the linked edition. It does not certify every recommendation or its suitability for an individual patient. Publisher access conditions may apply.